Photoactivatable ion channel modulator
US-2024409594-A1 · Dec 12, 2024 · US
Methods and compositions involving NKG2D inhibitors and cancer
US10040853B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10040853-B2 |
| Application number | US-201214343543-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 7, 2012 |
| Priority date | Sep 9, 2011 |
| Publication date | Aug 7, 2018 |
| Grant date | Aug 7, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Embodiments methods and compositions involving inhibitors of the immunoreceptor Natural Killer Group 2, Member D, (NKG2D) for inhibiting tumor progression and treating cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for inhibiting tumor progression, the method comprising administering to a subject that has been determined to have NKG2D-expressing cancer cells a composition comprising an anti-NKG2D ligand antibody or NKG2D ligand-binding polypeptide. 2. The method of claim 1 , wherein the NKG2D ligand antibody or ligand binding polypeptide inhibitor interferes with the NKG2D-binding of one or more endogenous NKG2D ligands on a cancer cell. 3. The method of claim 1 , wherein the polypeptide is an isolated antibody. 4. The method of claim 3 , wherein the isolated antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody, a human antibody, or a single chain antibody. 5. The method of claim 3 , wherein the isolated antibody is a human antibody. 6. A method for treating cancer comprising administering to NKG2D-expressing cancer cells in a subject that has been determined to have NKG2D-expressing cancer cells a composition comprising an anti-NKG2D ligand antibody or NKG2D ligand-binding polypeptide. 7. The method of claim 6 , wherein the polypeptide is an isolated antibody. 8. The method of claim 7 , wherein the isolated antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody, a human antibody, or a single chain antibody. 9. The method of claim 7 , wherein the isolated antibody is a human antibody. 10. The method of claim 1 , wherein the ligand comprises MIC or ULBP. 11. The method of claim 6 , wherein the ligand comprises MIC or ULBP. 12. The method of claim 1 , wherein the cancer cells comprise ovarian, breast, prostate, or colon cancer cells. 13. The method of claim 6 , wherein the cancer cells comprise ovarian, breast, prostate, or colon cancer cells. 14. The method of claim 1 , wherein the method comprises administering to the subject a composition comprising a NKG2D ligand-binding polypeptide.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
F(ab')2 · CPC title
- A61K38/17Primary
from animals; from humans {(enzyme inhibitors A61K38/005)} · CPC title
against receptors or cell surface proteins · CPC title
against the lectin superfamily, e.g. CD23, CD72 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10040853B2 cover?
- Embodiments methods and compositions involving inhibitors of the immunoreceptor Natural Killer Group 2, Member D, (NKG2D) for inhibiting tumor progression and treating cancer.
- Who is the assignee on this patent?
- Spies Thomas, Spies Veronika, Hutchinson Fred Cancer Res
- What technology area does this patent fall under?
- Primary CPC classification A61K38/17. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).